Dr. Samuel Baharestani, MD

Dr. Baharestani practices at North Shore Eye Care Hearing Services in Smithtown, New York.

Dr. Baharestani's NPI, 1730355116, was assigned on May 5, 2008. Dr. Baharestani graduated from New York University School of Medicine in 2007. Dr. Baharestani holds New York license 252341.

Dr. Baharestani's primary practice is North Shore Eye Care Hearing Services, at 260 Middle Country Rd, Smithtown, NY 11787 in Suffolk County. The practice phone is (631) 265-8780.

Dr. Baharestani's primary practice is North Shore Eye Care Hearing Services in Smithtown, New York. The medical group on file is Nassau University Medical Center (NUMC), Department of Psychiatry and Behavioral Sciences. Dmand AI also links Dr. Baharestani to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Baharestani practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Baharestani's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Baharestani is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Baharestani's licenses on file in 4 states: New York, Indiana, Kentucky and Ohio.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Baharestani treats.

CMS data shows 2,638 Medicare services from Dr. Baharestani across 20 procedure codes in 2024, for 749 Medicare patients. Medicare paid $247,284 for them.

CMS counts 749 Medicare patients who saw Dr. Baharestani in 2024. The largest group is 65 to 74, with 351 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.03, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Baharestani's median patient age at 65, with 63% women.

In 2024, Dr. Baharestani wrote 592 Medicare Part D claims for 385 patients. 83% of them were for generic drugs. CMS names the drug for 528 of them, across 5 drugs with 11 or more claims each, at $36,546 in total drug cost. In 2023, CMS named 542 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Baharestani for performance year 2024, reported as part of a group. Dr. Baharestani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 9 papers to Dr. Baharestani, published from 2004 to 2015. The most frequent topics are Cells, Cultured, Culture Media, Conditioned and Electromagnetic Fields. Dr. Baharestani's most frequent co-authors are Edward I. Chang, MD, Julia Nemiroff, MD and Oren M. Tepper, MD.

CMS Open Payments shows 333 general payments to Dr. Baharestani from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Amgen Inc. paid the most, $82,555.

Dmand AI lists 1 award for Dr. Baharestani.

Dr. Baharestani graduated from New York University School of Medicine in 2007. Dr. Baharestani is a member of AACS and AAO.

Dr. Baharestani is in network with 17 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.